title: The therapeutic monoclonal antibody market.
abstract: Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety of diseases, and many of these products have also been approved for other global markets. At the current approval rate of ∼ four new products per year, ∼ 70 monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly $125 billion.
authors.affiliation: a BioProcess Technology Consultants, Inc. ; Woburn , MA USA.
authors.forename: Dawn M
authors.initials: DM
authors.lastname: Ecker
authors.forename: Susan Dana
authors.initials: SD
authors.lastname: Jones
authors.forename: Howard L
authors.initials: HL
authors.lastname: Levine
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D017277:Drug Approval; D005060:Europe; D006801:Humans; D040541:Marketing; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal